

# Pharmaceutical Benefits Advisory Committee

---

Email: PBAC@health.gov.au

Address all mail to:  
PBAC Secretariat  
GPO Box 9848  
Canberra ACT 2601

## DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 SEPTEMBER 2025

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

### Item

### PBAC Advice

Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexaenoic acid

The sponsor requested the delisting of HCU Anamix junior LQ amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexaenoic acid in the form oral liquid 125 mL, 36 from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted the low number of services in the previous financial year and that there are limited alternatives available on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the product on the PBS, if possible. However, the sponsor decided to proceed with the delisting due to commercial reasons.

Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexaenoic acid

The sponsor requested the delisting of TYR Anamix junior LQ amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexaenoic acid in the form oral liquid 125 mL, 36 from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted the low number of services in the previous financial year and that there are limited alternatives available on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the product on the PBS, if possible. However, the sponsor decided to proceed with the delisting due to commercial reasons.

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexaenoic acid

The sponsor requested the delisting of MSUD Anamix Junior LQ amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexaenoic acid in the form oral liquid 125 mL, 36 from the Pharmaceutical Benefits Scheme (PBS).

The PBAC noted the low number of services in the previous financial year and that there are limited alternatives available on the PBS. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain the product on the PBS, if possible. However, the sponsor decided to proceed with the delisting due to commercial reasons.

Jodette Kotz  
Director, PBS Supply and Policy  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
21 August 2025